Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Table 1

Overall, high and low NLR subgroups patients’ characteristics and statistical differences between the two subgroups.

	Mean (min-max) or frequencies
	Overall	Low NLR	High NLR	value
Sex (male/female)	39/10	16/9	23/1	0.0106
Age (years)	75 (49–88)^┼	75 (49–88)^┼	74 (51–86)^┼	0.477
Etiology (HCV/Cripto/Alcol/others)	18/19/10/2	11/9/3/2	7/10/7/0	0.2102
Child-Pugh class (5/6/7/8/9)	17/21/7/3/1	8/10/5/1/1	9/11/2/2/0	0.6081
Neutrophil (/mm^3)	3485 (811–9130)^┼	2389 (811–6019)^┼	4533 (1920–9130)^┼	0.002
Lymphocyte (/mm^3)	1321 (360–2970)^┼	1553 (759–2970)^┼	1110 (360–1977)^┼	0.0107
Neutrophil/lymphocyte	3.25 (0.61–19.02)^┼; Median 2.03	1.5 (0.61–2.03)^┼	5.06 (2.19–19.02)^┼	0.0004
Platelet (/mm^3)	115.857 (51.000–243.000)^┼	111.041 (51.000–243.000)^┼	117.000 (53.000–188.000)^┼	0.6607
Platelet/lymphocyte	99 (33–391)^┼	75.43 (33.69–142.83)^┼	124.40 (52.50–391.78)^┼	0.0048
BCLC stage (B/C)	34/15	17/8	17/7	0.9244
Tumor size (<5/>5 cm)	23/26	13/11	10/15	0.4796
Number of tumors (<3/3–5/>5)	25/9/15	15/4/6	10/5/9	0.4293
Extrahepatic spread (absent/present)	49/0	25/0	24/0	1.0
Bilobar spread (absent/present)	18/31	12/13	6/18	0.1697
Ascites (absent/present)	37/12	20/5	17/7	0.6791
Albumin (g/dL)	3.70 (2.51–4.80)^┼	3.55 (2.51–4.46)^┼	3.83 (2.77–4.80)^┼	0.7460
Bilirubin (mg/dL)	1.04 (0.08–3.07)^┼	0.96 (0.08–2.42)^┼	1.11 (0.32–3.07)^┼	0.6570
INR	1.18 (0.92–1.68)^┼	1.20 (0.92–1.68)^┼	1.16 (1.00–1.40)^┼	0.1409
Creatinine (mg/dL)	0.90 (0.45–2.28)^┼	0.84 (0.45–1.80)^┼	0.95 (0.57–2.28)^┼	0.2198
GFR (mL/min)	96.56 (29.00–197.00)^┼	100.09 (29.00–197.00)^┼	93.63 (30.00–146.00)^┼	0.4283

Fisher’s exact test; χ²-test; Student’s t-test; ^┼min-max; BCLC = Barcelona Clinic Liver Cancer; Cripto = criptogenetic; GFR = glomerular filtration rate; HCV = hepatitis C virus; INR = International Normalized Ratio; NLR = neutrophil to lymphocyte ratio; PLR = platelet to lymphocyte ratio.